Official American Thoracic Society/Japanese Respiratory Society Clinical Practice Guidelines: Lymphangioleiomyomatosis Diagnosis and Management

Lymphangioleiomyomatosis (LAM) is a rare cystic lung disease that primarily affects women. The purpose of these guidelines is to provide recommendations for the diagnosis and treatment of LAM. Systematic reviews were performed to summarize evidence pertinent to our questions. The evidence was summar...

Full description

Saved in:
Bibliographic Details
Published inAmerican journal of respiratory and critical care medicine Vol. 194; no. 6; pp. 748 - 761
Main Authors McCormack, Francis X, Gupta, Nishant, Finlay, Geraldine R, Young, Lisa R, Taveira-DaSilva, Angelo M, Glasgow, Connie G, Steagall, Wendy K, Johnson, Simon R, Sahn, Steven A, Ryu, Jay H, Strange, Charlie, Seyama, Kuniaki, Sullivan, Eugene J, Kotloff, Robert M, Downey, Gregory P, Chapman, Jeffrey T, Han, MeiLan K, D'Armiento, Jeanine M, Inoue, Yoshikazu, Henske, Elizabeth P, Bissler, John J, Colby, Thomas V, Kinder, Brent W, Wikenheiser-Brokamp, Kathryn A, Brown, Kevin K, Cordier, Jean F, Meyer, Cristopher, Cottin, Vincent, Brozek, Jan L, Smith, Karen, Wilson, Kevin C, Moss, Joel
Format Journal Article
LanguageEnglish
Published United States American Thoracic Society 15.09.2016
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Lymphangioleiomyomatosis (LAM) is a rare cystic lung disease that primarily affects women. The purpose of these guidelines is to provide recommendations for the diagnosis and treatment of LAM. Systematic reviews were performed to summarize evidence pertinent to our questions. The evidence was summarized and discussed by a multidisciplinary panel. Evidence-based recommendations were then formulated, written, and graded using the Grading of Recommendations, Assessment, Development, and Evaluation approach. After considering the panel's confidence in the estimated effects, the balance of desirable (i.e., benefits) and undesirable (i.e., harms and burdens) consequences of treatment, patient values and preferences, cost, and feasibility, recommendations were formulated for or against specific interventions. These included recommendations for sirolimus treatment and vascular endothelial growth factor D testing and recommendations against doxycycline and hormonal therapy. Evidence-based recommendations for the diagnosis and treatment of patients with LAM are provided. Frequent reassessment and updating will be needed.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Instructional Material/Guideline-2
ObjectType-Feature-3
content type line 23
ISSN:1073-449X
1535-4970
DOI:10.1164/rccm.201607-1384st